Table 1.
miRNA | Cell type | Change in expression* |
Target genes | Effect of changed miRNA expression | Reference |
---|---|---|---|---|---|
let-7e | CD4+ T lymphocytes |
↑ | IL10 | Stimulation of development of Th1 and Th17 cells | [48] |
miR-17 | CD4+ T lymphocytes |
↑ | IKZF4 | Increased polarization of Th17 cells | [49] |
miR-19b | CD4+ T lymphocytes |
↑ | PTEN | Activation of Th17 cell differentiation | [49] |
miR-20b | CD4+ T lymphocytes |
↓ | RORC, STAT3 | Activation of Th17 cell differentiation | [50] |
mir-21 | CD4+ T lymphocytes |
↑ | SMAD7 | Activation of Th17 cell differentiation | [51] |
miR-23b | Spinal cord cells | ↓ | TAB2, TAB3, CHUK |
Stimulation of IL-17-mediated autoimmune inflammation | [38] |
miR-26a | Brain cells | ↓ | IL6 | Increased expression of Th17-mediated cytokines | [52] |
miR-29b | CD4+ T lymphocytes |
↑ | TBX21, IFNG | Regulation of Th1 cell differentiation | [53] |
miR-124 | Bone marrow macrophages |
↓ | CEBPA, SPI1 | Activation of phagocytic activity, inhibition of microglia differentiation |
[47] |
miR- 132/212 |
CD4+ T lymphocytes |
↓ | ACHE | Stimulation of T cell proliferation and production of IL-17 and IFN-γ; increased catalytic activity of acetylcholinesterase |
[54] |
miR-146a | Bone marrow stem cells |
↑ | PTGES2 | Inhibition of prostaglandin E2 synthesis | [45] |
miR-155 | CD4+ T lymphocytes |
↑ | SOCS1 | Stimulation of development of Th1 and Th17 cells | [42] |
↑ | INPP5D | Disturbance of myelin proliferation | [42] | ||
miR-301a | CD4+ T lymphocytes |
↑ | PIAS3 | Regulation of Th17 cell differentiation | [55] |
miR-326 | CD4+ T lymphocytes |
↑ | ETS1 | Stimulation of development and proliferation of Th17 cells |
[56] |
miR-873 | Primary astrocyte culture |
↑ | TNFAIP3 | Stimulation of production of inflammatory cytokines and increased demyelination of nerve fibers |
[57] |
*Hereinafter: an increase (↑) or decrease (↓) in miRNA expression upon experimental autoimmune encephalomyelitis.